INTRODUCTION
============

Mitotic errors predicted to produce aneuploidy have been recognized as a characteristic of human cancer cells since the late 1800s ([@B72]). Because of this correlation, aneuploidy was proposed to cause tumors in the early 1900s ([@B5], [@B6]). Aneuploidy is often accompanied by chromosomal instability (CIN), in which chromosomes are perpetually gained and lost during multiple divisions. Both aneuploidy and CIN serve as markers of poor prognosis in multiple tumor types ([@B36]; [@B83]).

Despite their high prevalence in human cancers, aneuploidy and CIN do not uniformly increase tumor incidence in mice. Numerous mouse models have been generated that develop aneuploidy and CIN as a consequence of chromosome missegregation (reviewed in [@B50]; [@B19]; [@B83]). A portion of mutations that induce aneuploidy and CIN do result in an elevated level of spontaneous and/or carcinogen-induced tumors, as initially predicted ([@B21]; [@B63], [@B64]; [@B31]; [@B49]; [@B56]). However, other models of aneuploidy and CIN exhibit tumor outcomes that do not differ from those in control animals ([@B10]; [@B24]; [@B3]; [@B30]; [@B34]; [@B48]). Most intriguingly, aneuploidy and CIN can promote tumors in certain contexts but inhibit them in others ([@B22]; [@B73]; [@B81]; [@B9]; [@B47]; [@B11]; [@B75]; [@B16]; [@B62]). Thus the effects of aneuploidy and CIN on tumors depend on their method of induction, as well as on the cellular context.

One of the causes of aneuploidy and CIN that can both promote and suppress tumors is heterozygous loss of the mitotic kinesin-like motor protein centromere-associated protein E (CENP-E; [@B75]; [@B62]). CENP-E is a large (∼312 kDa) protein that accumulates specifically during mitosis ([@B7]) and is required for accurate chromosome segregation. CENP-E localizes to kinetochores---the sites of chromosome attachment to spindle microtubules---through its C-terminal domain ([@B80]; [@B79]) and uses its 230-nm central stalk to allow its N-terminal motor to locate and bind microtubules ([@B28]). CENP-E functions in the mitotic checkpoint (also known as the spindle assembly checkpoint)---the major cell cycle checkpoint acting during mitosis to prevent chromosome missegregation---by facilitating recruitment of the mitotic checkpoint components BubR1, Mad1, and Mad2 to unattached kinetochores ([@B1]; [@B74]). Reduction or inhibition of CENP-E results in the chronic misalignment of one or a few chromosomes at or near spindle poles ([@B55]; [@B35]; [@B45]; [@B77]). Because the mitotic checkpoint is weakened, cells with reduced levels of CENP-E aberrantly enter anaphase in the presence of the misaligned, polar chromosomes in approximately one-fourth of divisions. As a result of these abnormal divisions, both sister chromatids of the polar chromosome are inherited by the same daughter cell, producing aneuploidy and a low rate of CIN. Cells with reduced levels of CENP-E have not shown discernible defects outside of mitosis ([@B74], [@B75]).

We recently demonstrated that it is the rate of chromosome missegregation, rather than the overall level of aneuploidy, that predicts the effect on tumors. Heterozygous loss of CENP-E did not cause tumor suppression in two contexts that did not exhibit prior CIN. In four contexts with existing low rates of CIN that developed tumors, reduction of CENP-E caused higher rates of CIN and cell death and reduced tumor incidence ([@B62]). However, it was unclear from these experiments whether high CIN inhibited tumor initiation or suppressed the growth and progression of already initiated tumors. This is a critical distinction because, in order to be a successful treatment strategy, increasing the rate of CIN must be sufficient to inhibit tumors that have already been initiated.

To test this question, we used tumor models expressing a mutant form of the adenomatous polyposis coli (APC) tumor suppressor. Mutations in *APC*, which predominantly encode truncated protein products, occur in ∼60% of spontaneous human colon cancers and cause the hereditary cancer syndrome familial adenomatous polyposis when present in the germline ([@B44]; [@B20]; [@B27]). Expression of truncation mutants of APC in mouse and human cells results in missegregation of small numbers of chromosomes, producing a large population of aneuploid cells ([@B15]; [@B25]; [@B69]). Mice that express the multiple intestinal neoplasia (*Min*) allele of *Apc*, which produces a truncated product of 850 amino acids, develop tens to hundreds of early-onset adenomatous intestinal polyps ([@B39]; [@B65]). Inhibition of tumor initiation versus tumor progression can be distinguished using intestinal tumor size and multiplicity. Here we show that combining low CIN from expression of the *Min* allele of *Apc* with low CIN due to reduction of CENP-E results in high CIN, elevated levels of cell death, and suppression of tumor growth, but not initiation, in both the small intestine and colon.

RESULTS AND DISCUSSION
======================

*CENP-E^+/−^;Apc^Min/+^* cells and tissues exhibit high CIN
-----------------------------------------------------------

Because expression of APC truncation mutants and reduction of CENP-E both cause low CIN, we predicted that combination of both insults would produce high CIN in doubly heterozygous cells. To test this, we crossed *CENP-E^+/−^* mice with *Apc^Min/+^* animals to produce wild-type, *Apc^Min/+^*, *CENP-E^+/−^*, and *CENP-E^+/−^;Apc^Min/+^* littermates. *CENP-E^+/−^;Apc^Min/+^* animals were born at expected frequencies and were overtly normal. To measure CIN, we scored abnormal mitotic figures consistent with chromosome missegregation in primary murine embryonic fibroblasts (MEFs) generated from embryonic day 14.5 (E14.5) embryos. These included polar chromosomes, which become persistently associated with the spindle pole and are characteristic of CENP-E impairment ([Figure 1A](#F1){ref-type="fig"}), as well as chromosomes that lag behind the separating masses of chromosomes during anaphase and telophase ([Figure 1B](#F1){ref-type="fig"}). Polar chromosomes are missegregated in ∼25% of divisions in primary MEFs with reduced levels of CENP-E ([@B74]), whereas lagging chromosomes are indicative of chromosome missegregation ([@B68]). Consistent with earlier results ([@B35]; [@B45]; [@B74], [@B75]), reduction of CENP-E produced elevated levels of polar chromosomes ([Figure 1, A and C](#F1){ref-type="fig"}). Truncation mutants of APC were reported to increase the percentage of lagging chromosomes ([@B15]; [@B25]; [@B69]). Accordingly, MEFs expressing the *Min* allele of *Apc* displayed lagging chromosomes at significantly higher frequency than wild-type or *CENP-E^+/−^* fibroblasts ([Figure 1, B and C](#F1){ref-type="fig"}). Double-mutant MEFs had levels of polar chromosomes similar to those in *CENP-E^+/−^* cells and rates of lagging chromosomes akin to those in *Apc^Min/+^* MEFs. Taken together, the double-mutant cells had a higher proportion of abnormal mitotic figures than either single mutant ([Figure 1C](#F1){ref-type="fig"}). Thus, combining two insults, each of which produces low CIN, results in high CIN in this in vitro context.

![Reduction of CENP-E increases the rate of chromosome missegregation in *Apc^Min/+^* cells and animals. *CENP-E^+/−^;Apc^Min/+^* cells show higher rates of abnormal mitotic figures consistent with chromosome missegregation than either *CENP-E^+/−^* or *Apc^Min/+^* singly heterozygous cells in vitro in primary MEFs (A--C) and in vivo in the mouse small intestine (D--F). (A) Polar chromosome (arrow) in primary MEF. (B) Lagging chromosome (arrow) in primary MEF. (C) Quantification of indicated mitotic defects; *n* \> 100 metaphase and \>150 total anaphase and telophase cells from each of three independent replicates. (D) Image of polar chromosomes (arrow) in murine small intestine. Right, enlargement of DNA in inset. (E) Lagging chromosome (arrow) in small intestine. Right, enlarged view of DNA in inset. (F) Quantification of mitotic defects in small intestine; *n* \> 30 metaphases or anaphases and telophases from three mice of each genotype (four mice in *Apc^Min/+^*). \**p* \< 0.05 vs. wild type, ^\#^*p* \< 0.05 vs. *CENP-E^+/−^;Apc^Min/+^*.](1981fig1){#F1}

To test whether the combination of heterozygous loss of *CENP-E* with mutation in *Apc* resulted in high CIN in vivo as well, we measured the frequency of abnormal mitotic figures in the crypts of 5-μm sections of murine small intestinal epithelium ([Figure 1, D--F](#F1){ref-type="fig"}). *CENP-E^+/−^* and *CENP-E^+/−^;Apc^Min/+^* doubly heterozygous intestines had increased levels of polar chromosomes ([Figure 1, D and F](#F1){ref-type="fig"}). *Apc^Min/+^* and *CENP-E^+/−^;Apc^Min/+^* intestines showed an increased frequency of lagging chromosomes ([Figure 1, E and F](#F1){ref-type="fig"}). Overall, double-mutant intestines had increased levels of both polar and lagging chromosomes, resulting in an elevated frequency of abnormal mitotic figures consistent with chromosome missegregation compared with *Apc* single mutants ([Figure 1F](#F1){ref-type="fig"}). These data demonstrate that reduction of CENP-E in cells expressing an APC mutant increases the rate of mitotic defects and CIN in vitro and in vivo.

Increased cell death in *CENP-E^+/−^;Apc^Min/+^* doubly heterozygous cells and animals
--------------------------------------------------------------------------------------

High rates of chromosome missegregation have been shown to result in cell death ([@B29]; [@B37]; [@B23]; [@B62]). To determine whether high CIN caused by reduction of CENP-E in the presence of mutant APC produced inviable cells, we quantitated levels of apoptosis in primary MEFs, as well as in sections of normal and tumorous small intestine. High CIN caused by reduction of CENP-E in *Apc^Min/+^* cells produced a marked increase in cleaved caspase-3 reactivity in primary MEFs ([Figure 2, A and B](#F2){ref-type="fig"}). Consistent with this, *CENP-E^+/−^;Apc^Min/+^*doubly heterozygous MEFs exhibited a growth disadvantage compared with wild-type, *CENP-E^+/−^*, and *Apc^Min/+^* singly heterozygous cells (Supplemental Figure S1A).

![High CIN increases cell death. (A) Image of cleaved caspase-3, a marker of apoptosis, in asynchronously cycling MEFS. Scale bar, 10 µm. (B) Quantification of cleaved caspase-3 showing that *CENP-E^+/−^;Apc^Min/+^* cells have higher rates of apoptosis than wild-type, *CENP-E^+/−^*, and *Apc^Min/+^* singly heterozygous cells with lower rates of CIN. *n* \> 500 cells per genotype from each of three separate experiments. \**p* \< 0.05 as compared to wild type. (C) Cleaved caspase-3 staining in *Apc^Min/+^* and *CENP-E^+/−^;Apc^Min/+^* adenomatous tumors. Scale bar, 50 µm. (D) Tumors from *CENP-E^+/−^;Apc^Min/+^* animals show an increase in apoptotic cell death compared with tumors from *Apc^Min/+^* singly heterozygous mice. Note that values from wild-type and *CENP-E^+/−^* animals are not shown because these animals do not develop tumors. *n* \> 500 cells from 13 *Apc^Min/+^* and 8 *CENP-E^+/−^;Apc^Min/+^* tumors. \**p* \< 0.05 as compared to *Apc^Min/+^*.](1981fig2){#F2}

In the small intestine, daughter cells are generated in the base of the crypts and migrate to the villi, where they undergo apoptosis ([@B78]). Consistent with this, levels of cleaved caspase-3 reactivity were negligible in the crypts and elevated in the villi. Expression of the *Min* allele of *Apc* increased the levels of apoptosis (Supplemental Figure S1B). Of interest, in the polyps of the small intestine, which have elevated rates of cell division, the double-mutant animals had significantly increased levels of apoptosis relative to *Apc^Min/+^* single mutants ([Figure 2, C and D](#F2){ref-type="fig"}). Thus, high CIN increases the level of apoptosis in vitro and in vivo.

High CIN suppresses progression of intestinal tumors
----------------------------------------------------

Mice expressing the *Min* allele of *Apc* develop intestinal polyps by 90 d of age ([@B39]). Measurement of the size and number of these early-onset tumors provides information regarding effects on tumor initiation versus tumor progression. Suppression of tumor initiation produces a reduced number of tumors of similar size, whereas inhibition of tumor progression results in tumors of reduced size. Inhibition of tumor progression may also result in a reduction of observed tumor number, if polyps do not progress sufficiently to be detected.

To test whether high CIN suppresses tumor progression, we determined intestinal tumor sizes. Tumor polyps were significantly smaller in double-mutant animals than in *Apc^Min/+^* animals in both the small intestine and the colon ([Figure 3, A and B](#F3){ref-type="fig"}). Diet is known to affect polyp development in *Apc^Min/+^* animals ([@B40]; [@B71]). Similar results were obtained in animals housed in a separate animal facility receiving different feed (Supplemental Figure S2, A and B). These data demonstrate that high CIN due to reduction of CENP-E in *Apc^Min/+^* mice suppresses tumor growth and progression in the small and large intestine and suggest that increasing the rate of CIN might be a successful chemotherapeutic strategy.

![High CIN suppresses the growth and progression of intestinal tumors in *Apc^Min/+^* mice. (A, B) High CIN due to reduction of CENP-E inhibits tumor progression, reducing the average size of tumors in the (A) small intestine and (B) colon of 91-d-old *CENP-E^+/−^;Apc^Min/+^* mice compared with tumors in age matched *Apc^Min/+^* littermates. In A, *n* = 237 tumors from eight *Apc^Min/+^* mice and 190 tumors from nine *CENP-E^+/−^;Apc^Min/+^* animals. In B, *n* = 16 and eight tumors from 15 *Apc^Min/+^* and 15 *CENP-E^+/−^;Apc^Min/+^* mice, respectively. (C, D) High CIN due to reduction of CENP-E suppresses tumor number in the small intestine (C) but not the colon (D) of 91-d-old *Apc^Min/+^* mice; *n* = 15 mice of each genotype. Note that wild-type and *CENP-E^+/--^* mice are not shown because they do not develop tumors at this time point. The boxes in C and D show the 25th percentile, median, and 75th percentile of the data, and the whiskers show the range of the complete data set. The median line for the *CENP-E^+/−^;Apc^Min/+^* genotype is not visible in D because it overlaps with the *x*-axis. These animals received Teklad Diet 8626. Similar results were obtained in an independent experiment in which animals were housed in a separate facility and received different chow (see Supplemental Figure S2). \**p* \< 0.05.](1981fig3){#F3}

High CIN does not inhibit the initiation of intestinal tumors
-------------------------------------------------------------

To determine whether high CIN inhibited tumor initiation as well as tumor progression, we examined tumor numbers. In the colon, tumor numbers were not significantly different in *CENP-E^+/−^;Apc^Min/+^* versus *Apc^Min/+^* mice in either of the animal cohorts receiving two different diets ([Figure 3D](#F3){ref-type="fig"} and Supplemental Figure S2D), indicating that high CIN suppresses tumor progression without inhibiting tumor initiation in this context.

In the small intestine, doubly heterozygous animals developed significantly fewer adenomas than *Apc^Min/+^* mice ([Figure 3C](#F3){ref-type="fig"} and Supplemental Figure S2C). However, it was unclear whether this was due to suppression of tumor initiation or because tumor progression was suppressed so thoroughly that initiated tumors did not progress sufficiently to be detected. To address this question, we tested the ability of *CENP-E^+/−^;Apc^Min/+^* and *Apc^Min/+^* small intestine cells to become tumor-initiating cells. In the *Apc^Min/+^* system, loss of the wild-type *Apc* gene converts *Apc^Min/+^* cells into tumor-initiating cells. Intestinal cells that have lost APC function can be discriminated from those that retain it using three-dimensional organoid culture. Organoids recapitulate multiple features of the intact gut, including cell type composition and crypt-villus structures ([@B53], [@B54]; [@B14]). Organoids containing wild- type *Apc* have a complex, highly branched morphology that mimics tissue organization in vivo ([@B53], [@B54]; [@B14], [Figure 4A](#F4){ref-type="fig"}). Consistent with our data in MEFs and in mice showing that reduction of CENP-E increases cell death in *Apc^Min/+^* cells, organoids from *CENP-E^+/−^;APC^Min/+^* animals grew more slowly than those from *Apc^Min/+^* littermates ([Figure 4B](#F4){ref-type="fig"}). As in normal intestinal epithelial tissue ([Figure 4C](#F4){ref-type="fig"}, white arrows), β-catenin is predominantly at the cell periphery in complex organoids expressing APC ([Figure 4D](#F4){ref-type="fig"}, left). In contrast, organoids that have lost APC function have a distinctive, rounded, cyst-like morphology ([@B14]; [@B42]; [Figure 4E](#F4){ref-type="fig"}). Like tumors of the small intestine in *Apc^Min/+^* animals ([Figure 4C](#F4){ref-type="fig"}, yellow arrowheads), cystic organoids have nuclear β-catenin staining, consistent with *Apc* loss ([@B42]; [Figure 4D](#F4){ref-type="fig"}, right).

![High CIN does not suppress tumor initiation in the small intestine. (A) Intestinal organoid with a branched, complex morphology typical of organoids retaining expression of wild- type APC. (B) Consistent with the elevated rates of cell death observed in *CENP-E^+/−^;Apc^Min/+^* MEFs and animals, complex organoids from *CENP-E^+/−^;Apc^Min/+^* animals increase in size more slowly than *Apc^Min/+^* organoids; *n* = 30 *Apc^Min/+^* and 40 *CENP-E^+/−^;Apc^Min/+^* organoids. (C) The layer of normal intestinal epithelium (white arrows) surrounding an intestinal tumor (yellow arrowheads) exhibits cell surface β-catenin staining, whereas β-catenin also exhibits nuclear localization in the tumor cells. (D) As in intact intestine, β-catenin localizes predominantly to the cell surface in complex organoids (left). In cystic organoids (right), β-catenin also shows nuclear staining, consistent with *Apc* loss and constitutive activation of Wnt signaling. (E) Cystic organoids, which are characteristic of *Apc* loss ([@B14]; [@B42]), show a rounded appearance that is distinct from the complex, branched structure of organoids expressing APC, as shown in A. Cystic organoids from *CENP-E^+/−^;Apc^Min/−^* tumor-initiating cells are substantially larger than cystic *Apc^Min/−^* organoids derived from *Apc^Min/+^* littermates on day 4 after plating. (F) A higher percentage of cells from *CENP-E^+/−^;Apc^Min/+^* than *Apc^Min/+^* small intestine form cystic organoids characteristic of *Apc* loss, demonstrating that high CIN does not inhibit tumor initiation in this context; *n* = 1782 organoids from *Apc^Min/+^* and 1514 organoids from *CENP-E^+/−^;Apc^Min/+^* animals. (G) Cystic organoids from tumor-initiating cells generated from *CENP-E^+/−^;Apc^Min/+^* normal intestinal epithelium are substantially larger on day 4 after plating than cystic organoids from *Apc^Min/+^* littermates. (H) In contrast, cystic organoids from mature *CENP-E^+/−^;Apc^Min/--^* tumor cells from adenomas of *CENP-E^+/−^;Apc^Min/+^* animals show no such growth advantage, suggesting that tumor-initiating cells are less sensitive than mature tumor cells to high CIN. (I) Growth rates of cystic organoids from tumor-initiating cells for the 10 d after sizes were measured in G, showing that *CENP-E^+/−^;Apc^Min/-^* tumor-initiating cells rapidly lose their early growth advantage. \**p* \< 0.05.](1981fig4){#F4}

To determine the rate at which tumor-initiating cells were generated, we scored the proportion of cystic organoids that formed from crypts of *Apc^Min/+^* and *CENP-E^+/−^;APC^Min/+^* mice. A previous study showed that increasing the rate of CIN due to reduced expression of the mitotic checkpoint gene Bub1 in p53^+/−^ mice accelerated loss of the chromosome containing the wild- type copy of p53 ([@B3]). This suggested that the formation of cystic organoids should be higher from *CENP-E^+/−^;APC^Min/+^* than *Apc^Min/+^* animals due to increased loss of the chromosome containing the wild-type allele of *Apc*. Consistent with this, the percentage of cystic organoids that formed from *CENP-E^+/−^;APC^Min/+^* animals was higher than that from *Apc^Min/+^* littermates ([Figure 4F](#F4){ref-type="fig"}). These data demonstrate that, although fewer adenomas are detected in the small intestine of *CENP-E^+/−^;APC^Min/+^* animals, high CIN accelerates the formation of tumor-initiating cells.

One potential caveat to the conclusion that high CIN suppresses tumor growth is that tumors that grew at the same rate in *CENP-E^+/−^;APC^Min/+^* and *Apc^Min/+^* animals would be smaller in *CENP-E^+/−^;APC^Min/+^* animals if tumor initiation were delayed in this genotype. The findings that tumor initiation is not inhibited in the small intestine or colon ([Figure 3, C and D](#F3){ref-type="fig"}, and Supplemental Figure 2, C and D), and that loss of wild-type *Apc* occurs earlier in organoids from *CENP-E^+/−^;APC^Min/+^* than from *APC^Min/+^* crypts ([Figure 4F](#F4){ref-type="fig"}) argue against this. However, if this were the case, two populations of tumors would be expected to arise in *CENP-E^+/−^;APC^Min/+^* animals---a population of large tumors that arose due to somatic recombination, as occurs in *APC^Min/+^* mice with a wild-type complement of CENP-E ([@B32]; [@B17]; [@B18]), and a population of small tumors that arose later due to loss of the copy of chromosome 18 containing the wild-type copy of *Apc*. The lack of a population of large tumors in the *CENP-E^+/−^;APC^Min/+^* animals ([Figure 3, A and B](#F3){ref-type="fig"}, and Supplemental Figure 2, A and B) further supports the conclusion that high CIN due to reduction of CENP-E suppresses the growth and progression of tumors in *APC^Min/+^* mice.

Tumor-initiating cells are less sensitive than mature tumor cells to high CIN
-----------------------------------------------------------------------------

Because high CIN suppresses tumor progression without inhibiting tumor initiation, this raises the question of whether tumor-initiating cells are more tolerant of high CIN than mature tumor cells. To test this, we isolated crypts from adenomas, as well as from normal small intestine. Organoids generated from normal intestine require a new or relatively recent loss of wild-type *Apc* to grow with a cystic morphology and thus provide a source of tumor-initiating cells. In contrast, cystic organoids from adenomas contain more mature tumor cells in which loss of the wild-type *Apc* gene occurred earlier. Remarkably, cystic organoids from *CENP-E^+/−^;Apc^Min/-^* tumor-initiating cells were substantially larger than cystic organoids from *Apc^Min/-^* tumor-initiating cells 4 d after seeding ([Figure 4, E and G](#F4){ref-type="fig"}). This was not true of the cystic organoids formed from the mature cells from adenomas, which were equivalent in size in both genotypes ([Figure 4H](#F4){ref-type="fig"}). Of interest, however, the tolerance of the tumor-initiating cells to high CIN did not persist, as cystic organoids from *CENP-E^+/−^;Apc^Min/--^* tumor-initiating cells did not outgrow cystic organoids from *Apc^Min/--^* tumor-initiating cells over the next 10 d ([Figure 4I](#F4){ref-type="fig"}). These data suggest that tumor-initiating cells are indeed less sensitive to cell death caused by high rates of chromosome missegregation. However, this insensitivity is rapidly lost.

Increasing CIN as chemotherapy
------------------------------

Therapeutically exploiting tumor suppression caused by high CIN to treat preexisting tumors requires that the inhibitory effects of high CIN be exerted on tumor growth and progression as opposed to tumor initiation. Here we show that converting low CIN into high CIN substantially inhibits tumor progression in the small intestine and colon. Moreover, our data suggest that relatively modest increases in chromosome missegregation can have substantial effects on cell death and tumor outcome. This is true not only when increases in chromosome missegregation occur early in tumor growth; tumors that have reached a size sufficient for diagnosis are also likely to be susceptible to small increases in the rate of CIN if they have a preexisting low rate of chromosome missegregation. We recently found that concentrations of the chemotherapy drug paclitaxel (Taxol) found in breast tumors are too low to cause mitotic arrest and instead induce chromosome missegregation on multipolar spindles ([@B82]). It appears that this commonly used chemotherapeutic agent kills cells in patient tumors by causing an increase in the rate of chromosome missegregation, and is perhaps particularly effective in cells that have a preexisting low rate of CIN. Consistent with this, although patients with tumors classified as CIN have poorer outcomes than those with chromosomally stable tumors ([@B8]), when CIN tumors are subdivided based on the level of expression of CIN genes, patients with breast, ovarian, gastric, and lung cancer whose tumors have the highest level of CIN have improved recurrence- or metastasis-free survival relative to patients with tumors containing a lower rate of CIN ([@B4]). Similarly, breast cancer patients with high CIN tumors, based on clonal variability in fluorescent in situ hybridization analysis, outlived patients with tumors exhibiting low CIN ([@B52]). Thus, multiple human data sets substantiate our mouse models showing that increasing the rate of chromosome missegregation might be a useful therapeutic strategy, particularly in tumors that already exhibit a low rate of CIN.

The major concern regarding the intentional generation of aneuploidy and CIN is their potential to initiate additional tumors. However, multiple animal models with elevated levels of aneuploidy and CIN are not tumor prone. These include animals that express a kinase-dead version of the Bub1 mitotic checkpoint protein ([@B48]), a dominant-negative fragment of Bub1 ([@B10]), or ∼75% of the endogenous level of Bub1 ([@B24]; [@B3]; [@B30]), as well as those with hypomorphic expression of the anaphase-promoting complex/cyclosome cofactor Cdc20 ([@B34]). In contrast, other animal models that exhibit aneuploidy and CIN do develop increased levels of spontaneous, carcinogen-induced and/or genetically driven tumors. Animals with similar levels of aneuploidy can have no tumor burden, a slightly increased tumor incidence, or a striking phenotype in which the majority of animals develop tumors (reviewed in [@B50]; [@B19]; [@B83]). In addition, mutation of genes resulting in aneuploidy and CIN can promote tumors in some contexts but suppress them in others. One example of this is heterozygous loss of BubR1, which increases colon tumor formation but decreases the incidence of small intestine tumors in *Apc^Min/+^* mice ([@B47]). Although the reason for this is not clear, most genes whose mutation leads to aneuploidy and CIN, including BubR1, have been implicated in functions outside of chromosome segregation that could reasonably be expected to affect tumor phenotype, including cell death pathways and the DNA damage response ([@B61]; [@B2]; [@B13]; [@B83]). It may be that the nonmitotic roles of BubR1 are tissue specific. Although there is striking diversity in the tumor phenotypes of animals that exhibit aneuploidy and CIN, it is clear that aneuploidy and CIN are not sufficient to cause an increase in tumor burden.

A second concern regarding the therapeutic use of strategies to induce CIN is that increasing CIN may not be effective against chromosomally stable tumor cells, potentially including tumor-initiating cells. Chromosomally stable tumor cells may benefit from combination therapy in which one drug that causes CIN is used to sensitize tumor cells to treatment with a second CIN-inducing drug, such as paclitaxel. In this case, tumor-specific targeting may be necessary for at least one of the treatments to prevent lethality in rapidly dividing, normal cells.

Intriguingly, treatments that cause chromosome missegregation in diploid cells do not necessarily produce persistently aneuploid cell populations. Experimentally inducing CIN in chromosomally stable cells produces only a transient increase in aneuploidy ([@B66], [@B67]). Chromosomally stable cancer cell lines have also been shown to exhibit aberrant mitotic divisions expected to produce aneuploid progeny, yet they maintain a relatively stable consensus karyotype over many generations ([@B51]).

Even if aneuploidy does result from pharmacologically increasing CIN, aneuploidy has been shown to cause a growth defect in yeast and murine cells under optimal conditions ([@B70]; [@B76]). Similarly, human skin fibroblasts trisomic for chromosome 21 grow more slowly than diploid skin fibroblasts ([@B57]). However, several studies show that specific aneuploid karyotypes can confer a growth advantage in response to certain stresses. In yeast, preexisting aneuploidy can result in accelerated growth in response to particular environmental stresses, and specific aneuploidies can evolve to overcome functional insufficiencies or adapt to environmental challenges ([@B46]; [@B43]; [@B26]; [@B38]). In pathogenic fungi, development of aneuploidy has been implicated as an adaptive response to confer azole resistance ([@B59], [@B58]). Similarly, aneuploidy is believed to confer a selective advantage in liver, as mice heterozygous for a gene on chromosome 16 that confers sensitivity to fumarylacetoacetate hydrolase (Fah) deficiency developed injury-resistant aneuploid liver nodules that had lost one copy of chromosome 16 after liver damage in the absence of Fah ([@B12]). In addition, human colonic cells grown in serum-free conditions acquire a third copy of chromosome 7 and outgrow diploid cells in serum-free media ([@B33]). These studies show that whereas aneuploidy often confers an overall growth disadvantage, specific aneuploidies can allow cells of various species to proliferate under conditions that are suboptimal for euploid cell growth. In addition, in some cases, what was believed to be stable aneuploidy has been reported to cause CIN. Aneuploid yeast strains often show an increase in karyotypic variation and genomic instability ([@B43]; [@B60]; [@B84]). Human chromosomally stable colorectal cancer cell lines (DLD1) with an extra copy of chromosome 7 or 13 show an increase in chromosome missegregation rates, as do amniotic fibroblasts that are trisomic for chromosome 13. Of interest, these cells predominantly missegregate the trisomic chromosome, suggesting that a portion of them revert to the diploid state ([@B41]).

Thus, although it is a concern, it is not a foregone conclusion that treatments aimed at inducing high CIN would produce aneuploidy in normal tissues or would increase the likelihood of secondary tumors later in life. We conclude that intentional induction of high CIN merits further consideration as a therapeutic strategy, at least in adult patients. It is now of interest to define the threshold of chromosome missegregation that is necessary to result in cell death, the types of cell death induced by high CIN, and the extent to which p53 function is required for tumor suppression mediated by high CIN.

MATERIALS AND METHODS
=====================

Intestinal sample collection, tumor counts, and measurements
------------------------------------------------------------

Mice were maintained in a C57BL/6 genetic background. Mouse experiments were conducted after approval by the University of Wisconsin--Madison Institutional Animal Care and Use Committee. Intestines from 90- or 91-d-old mice were collected and flushed with ice-cold phosphate-buffered saline (PBS), opened lengthwise, further washed with ice-cold PBS, and laid flat on bibulous paper and then fixed in 10% buffered Formalin overnight. Fixed tissues were then washed with 70% EtOH and stored in 70% EtOH until embedding. Counts and measurements of intestinal polyps were performed using a dissecting scope before embedding for histological analysis.

Cell culture
------------

MEFs were isolated from E14.5 embryos and maintained in DMEM (Life Technologies, Carlsbad, CA) containing 200 mM [l]{.smallcaps}-glutamine, 50 μg/ml penicillin-streptomycin, 10 mM nonessential amino acids, 100 mM sodium pyruvate, 1 mM β-mercaptoethanol, and 15% fetal calf serum (FCS) at 10% CO~2~, 3% O~2~, and 37°C. For fixed-cell analysis and videomicroscopy, cells were grown in media containing 10% FCS for 48 h before fixation or the start of time-lapse acquisition. Growth curves were seeded directly into media containing 10% FCS.

Immunofluorescence and immunohistochemistry
-------------------------------------------

Primary MEFs were washed with MTSB (100 mM 1,4-piperazinediethanesulfonic acid, pH 6.9, 30% glycerol, 1 mM ethylene glycol tetraacetic acid, and 1 mM MgSO~4~) and permeabilized in MTSB plus 0.05% Triton X-100 for 45 s at room temperature. Fixation was performed in MTSB plus 4% formaldehyde and 0.1% glutaraldehyde for 10 min at room temperature. For cleaved caspase-3 detection, glutaraldehyde was not included in the fixative solution. Coverslips were blocked overnight in Triton Block (0.2 M glycine, 2.5% fetal bovine serum \[FBS\], and 0.1% Triton X-100 in 1× PBS). Primary antibody incubation (α-tubulin YL1/2, 1:500, Serotec, Hercules, CA; cleaved caspase-3, 1:200, Cell Signaling, Danvers, MA) was performed for 1 h at room temperature in blocking solution. Coverslips were washed 3× in PBS plus 0.1% Triton X-100 and incubated in Alexa Fluor--conjugated secondary antibodies diluted 1:200 in PBS for 45 min at room temperature. Coverslips were washed 3× in PBS plus 0.1% Triton X-100, incubated for 3 min in 1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI) in PBS, rinsed 2× in PBS, and mounted in Vectashield (Vector Labs, Burlingame, CA) mounting medium.

Paraffin-embedded sections of 5-μm thickness were first deparaffinized in xylenes 3 × 10 min, rinsed in 100% ethanol, and hydrated in a series of 100, 95, 80, and 50% ethanol for 1 min each, followed by 5 min in double-distilled H~2~O. Antigen retrieval was performed in a pressure cooker set to 250°F for 4 min in citrate buffer (10 mM citric acid plus 0.05% Tween-20). Slides were then washed in PBS and blocked for 1 h at room temperature in PBS plus 10% FBS. Primary antibody incubation (α-tubulin DM1α, 1:200; cleaved caspase-3, 1:200, Cell Signaling) was performed overnight at 4°C in a humidified chamber. Slides were washed 3 × 5 min in PBS plus 0.1% Triton X-100 and incubated in secondary antibodies (Alexa Fluor, 1:200 in PBS) for 1 h at room temperature. After three subsequent washes, slides were incubated in 5 μg/ml DAPI in PBS for 10 min, washed 2× in PBS, and mounted using Vectashield (Vector Labs).

Images were acquired using a Nikon Eclipse Ti-E inverted microscope with a Hamamatsu ORCA Flash 4.0 camera using 10× (0.3 numerical aperture \[NA\]), 40× (0.75 NA), or 100× (1.4 NA) objectives. Image acquisition, analysis, and processing were performed using Nikon Elements AR. Autoquant was used for deconvolution. Images shown are maximum projections of z-stacks except in [Figures 1E](#F1){ref-type="fig"} and 4 where single *z*-planes are shown.

Organoids
---------

Intestines were harvested from 65-d-old mice, and crypt fractions were isolated as described ([@B85]). Crypts were seeded in Matrigel (9.2 mg/ml; BD). Adenomas were digested with 75 U/ml collagenase for 30 min at 37°C. Cultures were fed DMEM/F12 Advanced (Life Technologies) media containing 40 ng/ml epidermal growth factor (PeproTech, Rocky Hill, NJ), 50 ng/ml Noggin (PeproTech), and 250 ng/ml R-spondin (R&D, Minneapolis, MN) every other day. For growth curves, saved coordinates for each plate were visited every day (days 4--14), and images were acquired using a 10× (0.3 NA) objective and Hamamatsu Orca FLASH 4.0 camera driven by Nikon Elements software.

For immunofluorescence, organoids were fixed with 4% formaldehyde in MTSB for 30 min at room temperature and transferred to sieve wells in MTSB plus 0.05% Triton. Sieve wells consist of two adjacent wells that are open on the top and separated by a microporous membrane. The sieve well halves, designed to hold ∼100 μl each, are micromilled (PCNC 770; Tormach, Waunakee, WI) into separate pieces of polystyrene (PS; 52420098; MSC Industrial Supply, Melville, NY). With a microporous membrane (1221420; Maine Manufacturing, Sanford, ME) sandwiched between them, the PS halves are solvent bonded via acetonitrile (271004; Sigma-Aldrich, St. Louis, MO). The top of the bonded device is coated with a film of wax, and the outer faces of the bonded device are sealed with an optical adhesive (04729757001; Roche, Basel, Switzerland). Organoids were blocked for 1 h in PBS + 10% FBS and stained with β-catenin antibody (Cell Signaling) overnight at 4°C. Secondary antibody staining was done with Alexa Fluor 555 anti-rabbit for 1 h at room temperature. Organoids were imaged through No. 1.5 coverslips on a Nikon Ti-E inverted microscope using a 100× (1.4 NA) objective and a Hamamatsu Orca FLASH4 camera driven by Nikon Elements software.

Statistical analysis
--------------------

Statistical analysis was performed using MSTAT 6.1.4 software ([mcardle.wisc.edu/mstat/](http://mcardle.wisc.edu/mstat/)). Outliers were determined using Grubbs' method and excluded from analysis. Differences between samples were tested using the Wilcoxon rank sum test (tumor numbers, organoid analysis), chi-squared test (cell death, polar and lagging chromosomes), and the Sen--Adichie test (rates of growth/increase). Error bars represent SEM unless otherwise indicated.
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APC

:   adenomatous polyposis coli

CENP-E

:   centromere-associated protein E

CIN

:   chromosomal instability

MEF

:   murine embryonic fibroblast

Min

:   multiple intestinal neoplasia.
